Eli Lilly & Co. Upgraded by Ned Davis Research to “Buy” (LLY)
Eli Lilly & Co. (NYSE:LLY) was upgraded by equities researchers at Ned Davis Research from a “neutral” rating to a “buy” rating in a research report issued on Monday, AnalystRatings.Net reports.
LLY has been the subject of a number of other recent research reports. Analysts at Barclays downgraded shares of Eli Lilly & Co. from an “equal weight” rating to an “underweight” rating in a research note to investors on Friday. They now have a $51.00 price target on the stock, down previously from $58.00. Separately, analysts at BMO Capital Markets downgraded shares of Eli Lilly & Co. from a “market perform” rating to an “underperform” rating in a research note to investors on Wednesday, January 8th. They now have a $50.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Eli Lilly & Co. in a research note to investors on Friday, December 13th. They now have a $52.00 price target on the stock. Five investment analysts have rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $53.77.
Shares of Eli Lilly & Co. (NYSE:LLY) traded up 1.03% on Monday, hitting $52.465. 1,085,878 shares of the company’s stock traded hands. Eli Lilly & Co. has a 52 week low of $47.53 and a 52 week high of $58.40. The stock has a 50-day moving average of $50.55 and a 200-day moving average of $51.16. The company has a market cap of $56.673 billion and a price-to-earnings ratio of 11.88.
Eli Lilly & Co. (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 23rd. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.04 by $0.07. The company had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.76 billion. During the same quarter in the prior year, the company posted $0.79 earnings per share. The company’s quarterly revenue was up 6.1% on a year-over-year basis. On average, analysts predict that Eli Lilly & Co. will post $4.14 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Monday, March 10th. Shareholders of record on Friday, February 14th will be given a dividend of 0.49 per share. This represents a $1.96 dividend on an annualized basis and a yield of 3.77%. The ex-dividend date of this dividend is Wednesday, February 12th.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.